Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders.
Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders.
复制标题
DOI：
10.1097/mop.0000000000000179
复制
发表时间：
2015-02
影响因子：
3.6
通讯作者：
Boelens JJ
中科院分区：
文献类型：
--
作者：
Shenoy S;Boelens JJ
The role of hematopoietic stem cell transplantation (HCT) in non-malignant disorders (NMD) has increased exponentially with the recognition that multiple diseases can be controlled or cured of engrafted donor derived cells. This review provides an overview of advances made in alternative donor transplants for NMD. Stem cell sources, novel transplant methods, and sophisticated supportive care have simultaneously made giant strides toward improving safety and efficacy of HCT. This has led to the utilization of marrow, cord, peripheral blood stem cell and haploidentical stem cells sources, and novel reduced toxicity or reduced intensity conditioning regimens to transplant NMD groups such as immune disorders, marrow failure syndromes, metabolic disorders and hemoglobinopathies. HCT complications such as graft rejection, infections, and graft versus host disease are better combated in this modern era of transplant, with decreased late effects and better survival. These aspects of HCT for NMD are discussed. This review presents progress made in the realm of HCT for NMD. It advocates for consideration of alternative donor transplants in the absence of HLA matched siblings when indicated by disease severity. The ultimate goal is to provide curative transplant options for more patients with NMD that can benefit from this intervention, prior to detrimental outcomes.
